We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · June 01, 2022

Cabozantinib Plus Nivolumab in Patients With mUC Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Clin. Cancer Res 2022 Apr 01;28(7)1353-1362, DM Girardi, SA Niglio, A Mortazavi, R Nadal, P Lara, SK Pal, B Saraiya, L Cordes, L Ley, OS Ortiz, J Cadena, C Diaz, H Bagheri, B Redd, SM Steinberg, R Costello, KS Chan, MJ Lee, S Lee, Y Yu, S Gurram, HJ Chalfin, V Valera, WD Figg, M Merino, A Toubaji, H Streicher, JJ Wright, E Sharon, HL Parnes, YM Ning, DP Bottaro, L Cao, JB Trepel, AB Apolo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading